When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

Panelists discuss how cardiovascular toxicity remains a significant concern with certain tyrosine kinase inhibitors (TKIs) used in chronic myeloid leukemia (CML) treatment, particularly with the older ...

Panelists discuss how eliminating the strict mealtime restrictions with the new nilotinib formulation addresses a significant unmet need in chronic myeloid leukemia (CML) treatment by reducing ...